Vivek Mittal
Partner and Managing Director
San Francisco Bay Area · 1 connectionNot on Unlinked · Imported profile. Is this you? Claim it
Is this about you? Request removal
About
San Francisco Bay Area (US) 500 connections • 3,438 followers Hindi [View Publication](https://linkedin.com/redir/redirect?url=healthadvances.com/whitepaper/health-advances-unlocking-potential-cures-crispr.pdf&urlhash=oPem&trk=public_profile_publication-button) As traditional specialty drug markets have become increasingly crowded, large pharmaceutical companies and biotech companies alike have successfully turned previously ignored rare diseases into a robust business model. Are these first-mover products protected from competition by virtue of being in orphan markets? Here, we argue that meaningful product differentiation is required for new drugs to enjoy rapid clinical development and commercial success traditionally associated with orphan markets. Show less Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses. The current crop of molecular diagnostics acquisitions – espcially those made by nontraditional buyers – must mature prior to the commencement of additional M&A activ
Experience
Not listed.